Bioceltix (WAR:BCX) EBITDA Margin %: 0.00% (As of Mar. 2026)


WAR:BCX Bioceltix SA WAR:BCX
21 GF Score
Price zł87.80
! 1 Warning Sign
View Full Analysis

What is Bioceltix EBITDA Margin %?

Bioceltix WAR:BCX +0.11% 21 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates WAR:BCX with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Bioceltix ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioceltix's EBITDA for the three months ended in Mar. 2026 was zł-5.51 Mil. Bioceltix's Revenue for the three months ended in Mar. 2026 was zł0.00 Mil. Therefore, Bioceltix's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Bioceltix  (WAR:BCX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bioceltix EBITDA Margin % Related Terms

Bioceltix EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Bioceltix's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioceltix EBITDA Margin % Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Bioceltix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WAR:BCX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Bioceltix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioceltix EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioceltix's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bioceltix's EBITDA Margin % falls into.


WAR:BCX
21GF Score
Bioceltix SA WAR:BCX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioceltix EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bioceltix's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-14.344/0
= %

Bioceltix's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.506/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Bioceltix (WAR:BCX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioceltix and its competitors. According to the industry distribution chart, Bioceltix ranks #999999 out of 945 companies in the Biotechnology industry.
Is Bioceltix's EBITDA Margin % too high?
Bioceltix's current EBITDA Margin % is 0.00%. Based on the distribution chart, Bioceltix ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bioceltix has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Bioceltix's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioceltix ranks #999999 out of 945 companies for EBITDA Margin %. This places Bioceltix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioceltix and its competitors. Bioceltix's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioceltix stock overvalued right now?
Bioceltix (WAR:BCX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Bioceltix's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioceltix (WAR:BCX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioceltix Business Description

Address Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
21GF Score

Get the complete analysis for WAR:BCX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł87.80
Price